Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- المؤلفون: Jiang, Wei1 (AUTHOR); Wang, Peng-Ying1 (AUTHOR); Zhou, Qi1 (AUTHOR); Lin, Qiu-Tong1 (AUTHOR); Yao, Yao2 (AUTHOR); Huang, Xun1 (AUTHOR); Tan, Xiaoming1 (AUTHOR); Yang, Shihui1 (AUTHOR); Ye, Weicai3,4 (AUTHOR); Yang, Yuedong3 (AUTHOR) ; Bao, Yun-Juan1 (AUTHOR)
- المصدر:
Journal of Translational Medicine. 12/6/2023, Vol. 21 Issue 1, p1-16. 16p.
- الموضوع:
- معلومة اضافية
- نبذة مختصرة :
Background: With the development of cancer precision medicine, a huge amount of high-dimensional cancer information has rapidly accumulated regarding gene alterations, diseases, therapeutic interventions and various annotations. The information is highly fragmented across multiple different sources, making it highly challenging to effectively utilize and exchange the information. Therefore, it is essential to create a resource platform containing well-aggregated, carefully mined, and easily accessible data for effective knowledge sharing. Methods: In this study, we have developed "Consensus Cancer Core" (Tri©DB), a new integrative cancer precision medicine knowledgebase and reporting system by mining and harmonizing multifaceted cancer data sources, and presenting them in a centralized platform with enhanced functionalities for accessibility, annotation and analysis. Results: The knowledgebase provides the currently most comprehensive information on cancer precision medicine covering more than 40 annotation entities, many of which are novel and have never been explored previously. Tri©DB offers several unique features: (i) harmonizing the cancer-related information from more than 30 data sources into one integrative platform for easy access; (ii) utilizing a variety of data analysis and graphical tools for enhanced user interaction with the high-dimensional data; (iii) containing a newly developed reporting system for automated annotation and therapy matching for external patient genomic data. Benchmark test indicated that Tri©DB is able to annotate 46% more treatments than two officially recognized resources, oncoKB and MCG. Tri©DB was further shown to have achieved 94.9% concordance with administered treatments in a real clinical trial. Conclusions: The novel features and rich functionalities of the new platform will facilitate full access to cancer precision medicine data in one single platform and accommodate the needs of a broad range of researchers not only in translational medicine, but also in basic biomedical research. We believe that it will help to promote knowledge sharing in cancer precision medicine. Tri©DB is freely available at www.biomeddb.org, and is hosted on a cutting-edge technology architecture supporting all major browsers and mobile handsets. [ABSTRACT FROM AUTHOR]
No Comments.